Leuven, September 2, 2015 – Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the launch of a new website: www.oncurious.com
The new website provides more background on the compelling science behind the Company’s lead product TB-403 and its potential to improve the treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children.
Oncurious NV is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
For further information please contact:
Oncurious NV / ThromboGenics NV:
Wouter Piepers
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com
Citigate Dewe Rogerson
David Dible/Malcolm Robertson
Tel: +44 20 7638 9571
david.dible@citigatedr.co.uk
About Oncurious NV
Oncurious NV is an oncology company focused on the development of innovative medicines for the treatment of pediatric brain tumors. Oncurious is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
Oncurious plans to initiate a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. Enrolment of the first patient is expected by the end of 2015. BioInvent International is Oncurious’ co-development partner for the planned Phase I/IIa TB-403 clinical trial.
More information on Oncurious can be found at www.oncurious.com
Help employers find you! Check out all the jobs and post your resume.
